Hypophosphatemic Rickets

https://doi.org/10.1016/j.pcl.2018.09.004Get rights and content

Section snippets

Key points

  • Hypophosphatemia disorders can be divided conceptionally into those with increased fibroblast growth factor 23 (FGF23) levels (caused by mutations of extrarenal factors or by tumors) and those with normal or suppressed FGF23 (due to mutations tubular phosphate transporters). Rickets are the consequence of dysregulated phosphate transport and/or FGF23 excess.

  • X-linked hypophosphatemia is due to a hemizygous dominant mutation of the phosphate-regulating endopeptidase homolog, X-linked gene leading

Phosphate homeostasis

Phosphorus, the most abundant anion in the body,7 is an essential element for numerous cellular molecules, including nucleic acids, proteins, and lipids. It is critical for bone formation, and it is involved in acid-base regulation and cellular physiology. Rickets is a disease of the growth plate due to insufficient availability of PO4 (inorganic phosphorus [Pi]). It only affects growing children.2 PO4 deficiency may be due to poor absorption from the gut or renal wasting.

The average adult body

Clinical Findings

The clinical presentation of hypophosphatemia syndromes depends on the duration of hypophosphatemia and the age of patients (infancy and childhood vs adulthood). Different forms of hypophosphatemia cause similar, albeit not identical, clinical features and radiographical changes. Bone pain and deformities, fractures, disproportionate short stature, and dental abscesses are predominantly seen in chronically hypophosphatemic children. Adults may present with osteomalacia, bone pain, stiffness,

Hypophosphatemia syndromes

From a mechanistic and conceptual viewpoint, hypophosphatemia syndromes can be divided into those with increased FGF23 levels and those with normal or suppressed FGF23. Hypophosphatemia with increased FGF23 levels is caused by extrarenal factors, whereas hypophosphatemia with normal or suppressed FGF23 is due to mutations in genes encoding tubular PO4 transporters. Rickets are the consequence of dysregulated PO4 transport. Inherited disorders of renal PO4 handling contrast with acquired

Summary

Hypophosphatemic rickets, most due to the X-linked dominant form caused by pathogenic variants of the PHEX gene, continues to pose therapeutic challenges with important consequences for growth and bone development, high risk of fractions and poor bone healing, dental problems, and nephrolithiasis or nephrocalcinosis.

Conventional treatment consists of PO4 supplement and pharmacologically dosed calcitriol carefully monitoring for clinical efficacy and treatment-emergent adverse effects. Genetic

Acknowledgments

We thank Giuseppe Pascale for help in the design of the figures.

First page preview

First page preview
Click to open first page preview

References (138)

  • H. Olauson et al.

    Tissue expression and source of circulating alphaKlotho

    Bone

    (2017)
  • H. Kurosu et al.

    Regulation of fibroblast growth factor-23 signaling by klotho

    J Biol Chem

    (2006)
  • P.S. Rowe

    A unified model for bone-renal mineral and energy metabolism

    Curr Opin Pharmacol

    (2015)
  • D. Bacic et al.

    The renal Na+/phosphate cotransporter NaPi-IIa is internalized via the receptor-mediated endocytic route in response to parathyroid hormone

    Kidney Int

    (2006)
  • D. Miao et al.

    Cartilage abnormalities are associated with abnormal Phex expression and with altered matrix protein and MMP-9 localization in Hyp mice

    Bone

    (2004)
  • L.F. Gonzalez Ballesteros et al.

    Unexpected widespread hypophosphatemia and bone disease associated with elemental formula use in infants and children

    Bone

    (2017)
  • K. Kobayashi et al.

    Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia

    Life Sci

    (2006)
  • K. Kalantar-Zadeh et al.

    Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals

    Kidney Int Suppl

    (2010)
  • R.W. Winters et al.

    A genetic study of familial hypophosphatemia and vitamin D resistant rickets with a review of the literature

    Medicine (Baltimore)

    (1958)
  • D. Haffner et al.

    Disorders of phosphorus metabolism

  • S.S. Beck-Nielsen et al.

    Mutational analysis of PHEX, FGF23, DMP1, SLC34A3 and CLCN5 in patients with hypophosphatemic rickets

    J Hum Genet

    (2012)
  • T.H. Consortium

    A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium

    Nat Genet

    (1995)
  • J. Gattineni et al.

    Genetic disorders of phosphate regulation

    Pediatr Nephrol

    (2012)
  • C.A. Wagner et al.

    The SLC34 family of sodium-dependent phosphate transporters

    Pflugers Arch

    (2014)
  • V. Pavone et al.

    Hypophosphatemic rickets: etiology, clinical features and treatment

    Eur J Orthop Surg Traumatol

    (2015)
  • D.B. Lee et al.

    Intestinal phosphate absorption: influence of vitamin D and non-vitamin D factors

    Am J Physiol

    (1986)
  • B.K. Goldsweig et al.

    Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis

    Curr Osteoporos Rep

    (2015)
  • J. Blaine et al.

    Renal control of calcium, phosphate, and magnesium homeostasis

    Clin J Am Soc Nephrol

    (2015)
  • R.J.M. Bindels et al.

    Transport of calcium, magnesium, and phosphate

  • O.L. Bijvoet

    Relation of plasma phosphate concentration to renal tubular reabsorption of phosphate

    Clin Sci

    (1969)
  • R.A. Peraino et al.

    Phosphate transport by isolated rabbit cortical collecting tubule

    Am J Physiol

    (1980)
  • R. Villa-Bellosta et al.

    The Na+-Pi cotransporter PiT-2 (SLC20A2) is expressed in the apical membrane of rat renal proximal tubules and regulated by dietary Pi

    Am J Physiol Renal Physiol

    (2009)
  • C.A. Wagner et al.

    Genetic diseases of renal phosphate handling

    Nephrol Dial Transplant

    (2014)
  • C.A. Wagner et al.

    Renal phosphate handling and inherited disorders of phosphate reabsorption: an update

    Pediatr Nephrol

    (2017)
  • M. Levi et al.

    Cellular mechanisms of acute and chronic adaptation of rat renal P(i) transporter to alterations in dietary P(i)

    Am J Physiol

    (1994)
  • C. Wang et al.

    Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis

    Nat Genet

    (2012)
  • J. Biber et al.

    Regulation of phosphate transport in proximal tubules

    Pflugers Arch

    (2009)
  • T. Shimada et al.

    FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis

    J Bone Miner Res

    (2004)
  • N. Deliot et al.

    Parathyroid hormone treatment induces dissociation of type IIa Na+-P(i) cotransporter-Na+/H+ exchanger regulatory factor-1 complexes

    Am J Physiol Cell Physiol

    (2005)
  • J.Q. Feng et al.

    Do osteocytes contribute to phosphate homeostasis?

    Curr Opin Nephrol Hypertens

    (2009)
  • A. Consortium

    Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23

    Nat Genet

    (2000)
  • T.J. Weber et al.

    Serum FGF23 levels in normal and disordered phosphorus homeostasis

    J Bone Miner Res

    (2003)
  • M.T. Collins et al.

    Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D

    J Bone Miner Res

    (2005)
  • S. Liu et al.

    How fibroblast growth factor 23 works

    J Am Soc Nephrol

    (2007)
  • T. Berndt et al.

    Phosphatonins and the regulation of phosphate homeostasis

    Annu Rev Physiol

    (2007)
  • Y. Kinoshita et al.

    X-linked hypophosphatemia and FGF23-related hypophosphatemic diseases: prospect for new treatment

    Endocr Rev

    (2018)
  • E.G. Farrow et al.

    Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice

    Proc Natl Acad Sci U S A

    (2011)
  • M. Kuro-o et al.

    Mutation of the mouse klotho gene leads to a syndrome resembling ageing

    Nature

    (1997)
  • R.G. Erben

    alpha-Klotho's effects on mineral homeostasis are fibroblast growth factor-23 dependent

    Curr Opin Nephrol Hypertens

    (2018)
  • G. Chen et al.

    alpha-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling

    Nature

    (2018)
  • Cited by (47)

    • Tubulopathies

      2023, Medicine (Spain)
    • Disorders of Calcium and Phosphorus Metabolism

      2023, Avery's Diseases of the Newborn
    • Compounding vulnerabilities: Syndemics and the social determinants of disease in the past

      2022, International Journal of Paleopathology
      Citation Excerpt :

      This last process triggers RANKL expression, causing preosteoclasts to transform into osteoclasts that dissolve the bone matrix to release calcium and phosphorus into the blood (Brickley et al., 2020, p. 93). Genetic polymorphisms affecting phosphorus regulation (hypophosphatemic rickets) (Bitzan and Goodyer, 2019), calcium-sensing receptors (CaSR) (Wu et al., 2017), or VDR function (vitamin D-resistant rickets) (Liberman, 2007) can also result in skeletal rickets. Many diseases and iatrogenic factors also affect the bioavailability, synthesis, or metabolism of vitamin D, such as hyperparathyroidism, celiac disease, cystic fibrosis, chronic kidney disease, or medications used to treat high cholesterol (Holick, 2007).

    • Genetic and clinical profile of patients with hypophosphatemic rickets

      2022, European Journal of Medical Genetics
      Citation Excerpt :

      Phosphate deficiency is the primary defect in phosphopenic rickets, and is chiefly caused by genetic disorders of renal phosphate handling leading to impaired tubular reabsorption. The important genetic causes of phosphopenic rickets are FGF23 related X-linked dominant, autosomal dominant and autosomal recessive hypophosphatemic rickets (Bitzan and Goodyer, 2019). Impaired proximal tubular reabsorption of phosphate is also seen in patients with Dent disease, renal Fanconi syndrome and renal tubular acidosis (RTA).

    • Educational Case: Rickets

      2022, Academic Pathology
      Citation Excerpt :

      1,25-hydroxy-vitamin D has several systemic effects. However, 1,25-hydroxy-vitamin D acts on the kidney; nephron distal tubules respond to active vitamin D via the transient receptor potential vanilloid family (TRPV5), resulting in calcium reabsorption.20 Similarly, active vitamin D forms a heterodimeric complex with nuclear retinoid X receptor (RXR) within intestinal epithelial cells leading to the expression of TRPV6, which facilitates calcium absorption by the duodenum.19

    View all citing articles on Scopus

    Disclosure Statement: No disclosures.

    View full text